TY - JOUR AB - WD repeat‑containing protein 1 (WDR1) regulates the cofilin 1 (CFL1) activity, promotes cytoskeleton remodeling, and thus, facilitates cell migration and invasion. A previous study reported that autoantibodies against CFL1 and β‑actin were useful biomarkers for diagnosing and predicting the prognosis of patients with esophageal carcinoma. Therefore, the present study aimed to evaluate the serum levels of anti‑WDR1 antibodies (s‑WDR1‑Abs) combined with serum levels of anti‑CFL1 antibodies (s‑CFL1‑Abs) in patients with esophageal carcinoma. Serum samples obtained from 192 patients with esophageal carcinoma and other solid cancers. And s‑WDR1‑Ab and s‑CFL1‑Ab titers were analyzed using the amplified luminescent proximity homogeneous assay‑linked immunosorbent assay. Compared with those of healthy donors, the s‑WDR1‑Ab levels were significantly higher in the 192 patients with esophageal, whereas these were not significantly higher in the samples from patients with gastric, colorectal, lung, or breast cancer. In 91 patients treated with surgery, sex, tumor depth, lymph node metastasis, stage and C‑reactive protein levels were significantly associated with overall survival, as determined using the log‑rank test, whereas the squamous cell carcinoma antigen, p53 antibody and s‑WDR1‑Ab levels tended to be associated with a worse prognosis. Although no significant difference was observed in the survival between the positive and negative groups of s‑WDR1‑Abs or s‑CFL1‑Abs alone in the Kaplan‑Meier test, the patients in the s‑WDR1‑Ab‑positive and s‑CFL1‑Ab‑negative groups exhibited a significantly poorer prognosis in the overall survival analysis. On the whole, the present study demonstrates that the combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum may be a poor prognostic factor for patients with esophageal carcinoma. AD - Department of Clinical Oncology, Toho University Graduate School of Medicine, Tokyo 143-8541, Japan Department of Gastroenterological Surgery, Toho University School of Medicine, Tokyo 143-8541, Japan Stroke Center, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong 510630, P.R. China Department of Anesthesiology, Stroke Center, The First Affiliated Hospital and Health Science Center, Jinan University, Guangzhou, Guangdong 510630, P.R. China Port Square Kashiwado Clinic, Kashiwado Memorial Foundation, Chiba 260-0025, Japan Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan AU - Ito,Masaaki AU - Yajima,Satoshi AU - Suzuki,Takashi AU - Oshima,Yoko AU - Nanami,Tatsuki AU - Sumazaki,Makoto AU - Shiratori,Fumiaki AU - Wang,Hao AU - Hu,Liubing AU - Takizawa,Hirotaka AU - Li,Shu-Yang AU - Iwadate,Yasuo AU - Hiwasa,Takaki AU - Shimada,Hideaki AU - Ito,Masaaki AU - Yajima,Satoshi AU - Suzuki,Takashi AU - Oshima,Yoko AU - Nanami,Tatsuki AU - Sumazaki,Makoto AU - Shiratori,Fumiaki AU - Wang,Hao AU - Hu,Liubing AU - Takizawa,Hirotaka AU - Li,Shu-Yang AU - Iwadate,Yasuo AU - Hiwasa,Takaki AU - Shimada,Hideaki DA - 2023/03/01 DO - 10.3892/mi.2023.71 IS - 2 JO - Med Int KW - WD repeat‑containing protein 1 cofilin 1 esophageal carcinoma antibody biomarker overall survival PY - 2023 SN - 2754-3242 2754-1304 SP - 11 ST - The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma T2 - Medicine International TI - The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma UR - https://doi.org/10.3892/mi.2023.71 VL - 3 ER -